Most of the attention right now is on vaccines, but vaccines are only part of the battle against COVID-19. Dr. Mark DiNubile, Chief Medical Officer at BioAegis, joins KYW Newsradio In Depth to talk about what’s out there right now, the science behind COVID-19 treatments, and why he believes so strongly that gelsolin therapy can […]
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported that low levels of gelsolin are associated with severity and organ
No drug-related safety signals identified by the independent Data and Safety Monitoring Board. MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced that it has expanded its clinical trial in severe COVID-19
The leadership team of BioAegis Therapeutics will share their experiences this year as they reframed their strategy to address the COVID-19 threat to their employees and hustled to initiate a COVID-19 clinical trial for severe COVID-19 patients. When: Thursday, August 20, 2020 12:00 p.m. – 1:00 p.m. EDT Where: Online (GoToWebinar) Contact: WIB-Metro New York
BioAegis has been selected as a featured company in the upcoming BioNJ COVID-19 Rapid Fire Research Showcase. Our Chief Executive Officer and Co-founder, Dr. Susan Levinson, will present our goundbreaking recombinant human plasma gelsolin (rhu-pGSN) therapy. WHEN: Friday, June 5, 2020, 9:00 a.m. – 10:00 a.m. Register Now
June 5, 2020: BioNJ COVID-19 Rapid Fire Research Showcase Read More »
Steven Cordovano brings to BioAegis a sophisticated market perspective and broad investor network gained through years of investment experience as a highly successful fund manager. He has worked in finance and portfolio management for 25 years. Prior to BioAegis, Mr. Cordovano was a Partner with Trivalent Partners, where he assisted emerging growth companies in developing
VP, Corporate Development and Communications, Steven Cordovano Read More »
Lester Kobzik is a professor emeritus of Pathology at the Harvard Medical School and the Harvard T. H. Chan School of Public Health. His research interests center on lung disease and how the lung defends itself against inhaled toxic and infectious challenges. His work has characterized scavenger receptors on lung macrophages and how they function
Chief Scientific Advisor, Lester Kobzik, MD Read More »
Mark J. DiNubile, MD, FIDSA, has been a founding member of the BioAegis team and key advisor to BioAegis Therapeutics since its inception, providing leadership in clinical strategy, including serving as Chief Medical Officer. He brings to the table the rare combination of clinical and research expertise along with broad pharmaceutical industry experience, coupled with
Mark J. DiNubile, MD, FIDSA Read More »
Valerie Ceva is the Chief Operating Officer, bringing to BioAegis a record of accomplishments in life science business development, strategic consulting and global venture capital transactions. Prior to BioAegis, Ms. Ceva focused on emerging technology, supporting venture capital firms with investment strategy development and implementation and early stage companies in business model development, venture capital
Chief Operating Officer, Valerie Ceva, MBA Read More »
Susan Levinson is a co-founder and the CEO of BioAegis, with over 30 years of life sciences consulting and pharmaceutical experience spanning the entire value chain, from the lab bench to marketing. Prior to BioAegis, Dr. Levinson was the President of The Strategic Choice, a management consulting firm she founded after a successful career in
Chief Executive Officer, Susan L. Levinson, PhD. Read More »
LOCATION:
BioAegis Therapeutics
685 US Route 1
North Brunswick, NJ 08902
MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com
INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com
©2024 BioAegis® Therapeutics Inc.
Privacy Policy | Code of Business Conduct and Ethics | Terms of Use